Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
98M
-
Number of holders
-
41
-
Total 13F shares, excl. options
-
37.1M
-
Shares change
-
+1.47M
-
Total reported value, excl. options
-
$58.7M
-
Value change
-
+$2.05M
-
Put/Call ratio
-
0.19
-
Number of buys
-
14
-
Number of sells
-
-25
-
Price
-
$1.58
Significant Holders of aTYR PHARMA INC - COMMON STOCK (ATYR) as of Q3 2023
53 filings reported holding ATYR - aTYR PHARMA INC - COMMON STOCK as of Q3 2023.
aTYR PHARMA INC - COMMON STOCK (ATYR) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 37.1M shares
of 98M outstanding shares and own 37.89% of the company stock.
Largest 10 shareholders include FEDERATED HERMES, INC. (10.2M shares), FMR LLC (8.56M shares), Stonepine Capital Management, LLC (4.63M shares), Tikvah Management LLC (2.46M shares), Alyeska Investment Group, L.P. (2.46M shares), VANGUARD GROUP INC (2.28M shares), CITADEL ADVISORS LLC (1.78M shares), BlackRock Inc. (1.36M shares), GEODE CAPITAL MANAGEMENT, LLC (587K shares), and RENAISSANCE TECHNOLOGIES LLC (506K shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.